SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Jazz Estimates $755 Million Q3 2026 Pre-Tax IPR&D Charge

Jazz Pharmaceuticals estimates a Q3 2026 GAAP and non-GAAP pre-tax IPR&D charge of $755 million in connection with its Actio Biosciences acquisition.

JAZZ

Story updates

08:18:04 PM UTC
SquawkNews
JAZZ PHARMACEUTICALS: ESTIMATED Q3 2026 IPR&D CHARGE TO UNFAVORABLY IMPACT GAAP EPS & NON-GAAP ADJ E

Related stories